Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
Tsimberidou AM, Paterakis G, Androutsos G, Anagnostopoulos N, Galanopoulos A, Kalmantis T, Meletis J, Rombos Y, Sagriotis A, Symeonidis A, Tiniakou M, Zoumbos N, Yataganas X. Tsimberidou AM, et al. Among authors: galanopoulos a. Leuk Res. 2002 Feb;26(2):143-54. doi: 10.1016/s0145-2126(01)00106-0. Leuk Res. 2002. PMID: 11755464
The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms.
Diamantopoulos PT, Solomou E, Symeonidis A, Pappa V, Kotsianidis I, Galanopoulos A, Pontikoglou C, Anagnostopoulos A, Vassilopoulos G, Zikos P, Hatzimichael E, Papaioannou M, Megalakaki A, Vassilakopoulos T, Dimou M, Tsokanas D, Papoutselis MK, Papageorgiou S, Kourakli A, Papadaki H, Panayiotidis P, Viniou NA. Diamantopoulos PT, et al. Among authors: galanopoulos a. Am J Hematol. 2023 May;98(5):E119-E122. doi: 10.1002/ajh.26886. Epub 2023 Mar 1. Am J Hematol. 2023. PMID: 36808739 Free article. No abstract available.
Treatment of patients with myelodysplastic syndrome with amifostine.
Galanopoulos A, Kritikou-Griva E, Gligori J, Michalis E, Grigoraki V, Marinakis T, Kakkas J, Tasiopoulou A, Anagnostopoulos NI. Galanopoulos A, et al. Leuk Res. 2001 Aug;25(8):665-71. doi: 10.1016/s0145-2126(01)00004-2. Leuk Res. 2001. PMID: 11397471 Clinical Trial.
Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response.
Viniou N, Terpos E, Galanopoulos A, Kritikou-Griva E, Akel S, Michalis E, Apostolidou E, Georgiadou D, Kouraklis A, Parharidou A, Kokkini G, Symeonidis A, Anagnostopoulos NI, Christakis JI, Tasiopoulou A, Loukopoulos D, Yataganas X. Viniou N, et al. Among authors: galanopoulos a. Ann Hematol. 2002 Apr;81(4):182-6. doi: 10.1007/s00277-002-0442-y. Epub 2002 Mar 27. Ann Hematol. 2002. PMID: 11976818 Clinical Trial.
FLT3 overexpression in acute promyelocytic leukemia patients without detectable FLT3-ITD or codon 835-836 mutations: a pilot study.
Lilakos K, Viniou NA, Mavrogianni D, Vassilakopoulos TP, Dimopoulou MN, Plata E, Angelopoulou MK, Variami E, Stavrogianni N, Liapi D, Xilouri I, Galanopoulos A, Ageloudi M, Panayiotidis P, Voulgarelis M, Rombos J, Meletis J, Yataganas X, Pangalis GA. Lilakos K, et al. Among authors: galanopoulos a. Anticancer Res. 2006 Mar-Apr;26(2A):1201-7. Anticancer Res. 2006. PMID: 16619525 Free article.
Prognostic significance of deletion of the long arm of chromosome 20 in patients with myelodysplastic syndrome (MDS): a study of the Greek MDS Study Group.
Galanopoulos AG, Symeonidis A, Kourakli A, Papadaki EA, Tsaftaridis P, Terpos E, Aktipi A, Roussou P, Protopappa M, Pappaioannou M, Zikos P, Speletas M, Parcharidou A, Laoutaris N, Anagnostopoulos NI, Meletis J, Pangalis GA, Zoumbos N, Viniou N; Hellenic MDS Study Group. Galanopoulos AG, et al. Eur J Haematol. 2007 Jan;78(1):89-90. doi: 10.1111/j.1600-0609.2006.00764.x. Eur J Haematol. 2007. PMID: 17302860 No abstract available.
Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.
Ximeri M, Galanopoulos A, Klaus M, Parcharidou A, Giannikou K, Psyllaki M, Symeonidis A, Pappa V, Kartasis Z, Liapi D, Hatzimichael E, Kokoris S, Korkolopoulou P, Sambani C, Pontikoglou C, Papadaki HA; Hellenic MDS Study Group. Ximeri M, et al. Among authors: galanopoulos a. Haematologica. 2010 Mar;95(3):406-14. doi: 10.3324/haematol.2009.010876. Epub 2009 Sep 22. Haematologica. 2010. PMID: 19773257 Free PMC article.
High frequency of human leukocyte antigen class II DRB1*1602 haplotype in Greek patients with myelodysplastic syndrome and of DRB1*1501 in the low-risk subgroup.
Kritikou-Griva E, Spyropoulou-Vlachou M, Tsagarakis NJ, Goumakou E, Vrani V, Galanopoulos A, Papadhimitriou SI, Androutsos G, Paterakis G, Stavropoulos-Giokas C. Kritikou-Griva E, et al. Among authors: galanopoulos a. Hum Immunol. 2012 Mar;73(3):278-81. doi: 10.1016/j.humimm.2011.12.013. Epub 2011 Dec 27. Hum Immunol. 2012. PMID: 22244918
Leukemic transformation in patients with myelodysplastic syndromes after treatment with granulocyte colony-stimulating factor.
Diamantopoulos PT, Chatzileonida T, Galanopoulos A, Yiakoumis X, Saridaki AM, Angelidis A, Papakostas E, Bazanis E, Sachanas S, Michael M, Pangalis GA, Anagnostopoulos NI, Meletis J, Viniou NA. Diamantopoulos PT, et al. Among authors: galanopoulos a. Leuk Lymphoma. 2012 Oct;53(10):2069-72. doi: 10.3109/10428194.2012.668679. Epub 2012 Apr 9. Leuk Lymphoma. 2012. PMID: 22360720 No abstract available.
100 results